GU Cancers 2024 | Racial disparities in MSRF management in ADT-treated prostate cancer

Neda Hashemi-Sadraei, MD, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, discusses racial and ethnic health disparities in prostate cancer treatment, specifically focusing on the use of androgen deprivation therapy (ADT) and its associated metabolic syndrome risk factors (MSRF). The retrospective observational cohort study revealed significant racial/ethnic differences in MSRF screening rates. Notably, minority populations had lower rates of MSRF screening compared to non-Hispanic white patients, emphasizing the urgent need for closer clinical attention, education, and innovative interventions to bridge these disparities. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.